Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

Data from the Women’s Intervention Nutrition Study found a reduction in dietary fat intake resulted in lower death rates in ER- and PR-negative breast cancer.

A study of triple-negative breast cancer patients found that adding bevacizumab to chemo resulted in higher pCR rates in those with basal-like disease.

The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.

A large study bolsters the evidence that black women who breastfeed have a lower risk of being diagnosed with ER- and triple-negative breast cancer.

Adding either carboplatin or bevacizumab to a neoadjuvant regimen increased rates of pathologic complete response in triple-negative breast cancer patients.

This slide deck covers the treatment of triple-negative breast cancer, a heterogeneous disease made up of numerous subtypes, and includes clinical variables that can help with prognosis and guide in treatment choice.

A new study shows that in some cases, inhibiting the growth of primary tumors can promote the spread of tumor cells to other parts of the body.


Subscribe to Triple-Negative Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.